UNSPSC 51282955: Esafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C15H17FN4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A6NT0I9X0K, chemically known as 1,8-naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo- but more generally known as esafloxacin, which bears US NIH Compound Identifier 208933. European Medicines Agency schedules Esafloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06606MIG.

The term ESAFLOXACIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 3, No. 3, 1989, List 29). ESAFLOXACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: FC1C(N2CC(N)CC2)NC2N(CC)CC(C(=O)C2C1)C(=O)O.

UNSPSC 51282955 Esafloxacin, a Commodity code, shows limited recent state and local procurement activity that aligns directly with the code's pharmaceutical scope. The recent opportunities record contains four solicitations, but only one—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic multi-source pharmaceuticals RFP—addresses pharmaceutical procurement in a manner potentially encompassing esafloxacin or similar antimicrobial agents. The three other opportunities (Seminole County's naloxone and drug deactivation systems, Tampa Fire Department's medical and first aid supplies, and Texas HHS Commission's direct-to-manufacturer prescription RFI) focus on distinct product categories or procurement mechanisms that fall outside the antibiotic pharmaceutical scope the code nominally represents. State and local buyers under this code typically source through cooperative purchasing vehicles and established pharmaceutical wholesaler networks rather than direct manufacturer contracts, as evidenced by MMCAP's reliance on AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson as the three authorized distribution channels.

The MMCAP RFP, issued January 20, 2026, with proposals due March 26, 2026, represents the most relevant recent activity. MMCAP operates across multiple states including Minnesota and Oregon, administered by the Minnesota Department of Administration's Office of State Procurement, and awards multiple contracts for generic pharmaceuticals based on price competitiveness (weighted at 75 percent), compliance with cGMP and DSCSA standards, EDI capability, and fixed pricing through contract term. Vendors must maintain relationships with at least two of the three authorized wholesalers and accept a 3 percent administrative fee on all purchases. Contract term is two years for new vendors, with optional MMCAP extensions or incumbent amendment alignment through June 30, 2028. The code shows sparse direct recent activity from individual municipalities or county health departments, suggesting that state and local pharmaceutical procurement flows primarily through established cooperative purchasing agreements rather than individual agency competitive bids.